Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Gene Aberrations
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Gene Aberrations (TOPARP-B): A Multicentre, Open-Label, Randomised, Phase 2 Trial
Lancet Oncol 2019 Dec 02;[EPub Ahead of Print], J Mateo, N Porta, D Bianchini, U McGovern, T Elliott, R Jones, I Syndikus, C Ralph, S Jain, M Varughese, O Parikh, S Crabb, A Robinson, D McLaren, A Birtle, J Tanguay, S Miranda, I Figueiredo, G Seed, C Bertan, P Flohr, B Ebbs, P Rescigno, G Fowler, A Ferreira, R Riisnaes, R Pereira, A Curcean, R Chandler, M Clarke, B Gurel, M Crespo, D Nava Rodrigues, S Sandhu, A Espinasse, P Chatfield, N Tunariu, W Yuan, E Hall, S Carreira, JS de BonoFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Advanced Prostate Cancer Center of Excellence
Visit our Advanced Prostate Cancer Center of Excellence for additional, in-depth coverage.